Robbins Geller Seeks $94M Fees In $400M Pfizer Class Deal
Robbins Geller Rudman & Dowd LLP, lead counsel in a shareholder class action accusing Pfizer Inc. of misleading investors about the off-label marketing of various drugs, asked a New York federal...To view the full article, register now.
Already a subscriber? Click here to view full article